

*Article 34*

**THE CLAIMS DEFINING THE INVENTION ARE:**

- SUB B1*
1. A composition for administration to animals including a combination of :
    - (a) at least one anti-arthritis agent selected from the group comprising
      - i) green-lipped mussel extract (GLME) and/or a pharmacologically active green lipped mussel product, and
      - ii) shark cartilage; with
    - (b) at least one enhancing agent selected from the group of:  
a bark product or extract exhibiting antioxidant properties, and  
chondroitin compounds, and  
deer velvet, and  
vitamin Eand wherein the agent enhances the effect of the anti-arthritis agent.
  2. A composition for administration to animals including a combination of :
    - (a) at least one anti-arthritis agent selected from the group comprising
      - i) green-lipped mussel extract (GLME) and/or a pharmacologically active green lipped mussel product, and
      - ii) shark cartilage; with
    - (b) at least one enhancing agent selected from the group of:  
a bark product or plant product or extract exhibiting antioxidant properties,  
and  
chondroitin compounds, and  
deer velvet, and  
vitamin Eand wherein the agent enhances the effect of the anti-arthritis agent.
  3. A composition as claimed in either claim 1 or claim 2 which includes either or both of a green-lipped mussel extract (GLME) and a pharmaceutically active green lipped mussel product, in combination with any one or more of:  
shark cartilage, pharmacologically active shark extract, and chondroitin sulphate.
  4. A composition as claimed in either claim 1 or claim 2 which includes an anti-inflammatory agent in combination with a chondroitin compound.
- SUB C1*

- SUB  
a)
5. A composition as claimed in either claim 1 or claim 2 which includes as the anti-inflammatory agent either or both of shark cartilage and pharmacologically active shark cartilage extract in combination with any one or more of:  
Enzogenol™, Pycnogenol™, a bark extract equivalent to Enzogenol™ or Pycnogenol™, chondroitin sulphate, and a chondroitin compound.
  6. A composition as claimed in any one of the preceding claims which includes, as an enhancing agent, Pycnogenol™.
  7. A composition as claimed in any one of the preceding claims which includes one or more anti-oxidants other than Enzogenol or equivalent bark extracts.
  8. A composition as claimed in claim 7 in which an anti-oxidant is vitamin E.
  9. A composition as claimed in any one of the preceding claims which includes deer velvet or a pharmacologically active extract thereof.
  10. A composition as claimed in any one of the preceding claims which includes additional glycosaminoglycans than those present in the selected anti-inflammatory or enhancing agents.
  11. A composition as claimed in any one of the preceding claims which green-lipped mussel extract (GLME) and/or a pharmacologically active green lipped mussel product in sufficient amount to provide gastro-intestinal protection against irritation by other components in the composition.
  12. A composition as claimed in any one of the preceding claims which also includes any one or more of the following components:  
a vitamin, glycine, lysine, methionine, glutamic acid, tyrosine, and compounds providing in a pharmacologically acceptable form one or more of the following elements: manganese, zinc, iron, magnesium, selenium, calcium, copper, potassium, cobalt.
  13. A composition as claimed in any one of the preceding claims which includes one or more pharmacologically active substances.

- sub  
a1
14. A composition as claimed in claim 13 in which a pharmacologically active substance is an anti-inflammatory other than those listed in claim 1.
15. A composition as claimed in any one of the preceding claims formulated to be suitable for addressing any one or more of the following conditions in animals: inflammation, arthritis, chronic joint pain.
16. A composition as claimed in any one of the preceding claims in any one or more of the following forms:  
as a bolus or tablet, in a capsule, as a slow release implant, as a liquid composition, as a gel, and as a paste.
17. A composition as claimed in any one of the preceding claims formulated for use with non-human mammals.
18. A method for addressing joint problems in non-human animals consisting of the administration of a composition as claimed in any one of the preceding claims.
19. A method as claimed in claim 18 in which the method of administration is oral.
20. A composition substantially as described herein with reference to the contained examples.
21. A method for addressing joint problems, substantially as described herein with reference to the contained examples.
- sub  
a2
22. The use of any two or more of:  
i) green-lipped mussel extract (GLME) and/or a pharmacologically active green lipped mussel product,  
ii) shark cartilage and/or pharmacologically active shark cartilage extract;  
and  
iii) an antioxidant bark extract,  
in the preparation of a composition for use in addressing any one or more of:  
a) inflammation;  
b) degenerative joint complaints;  
c) other cartiligenous degeneration;  
d) gastrointestinal sensitivity or irritation;  
e) cancerous tumours;
- Add  
a3
- Add  
a4